The involvement of immune dysfunction in the pathogenesis of
lung cancer has been extensively studied. However, the potential molecular mechanisms through which the
tumor immune response affects drug resistance are still unclear. Accordingly, in this study, we evaluated deviations in the immune cell landscape among patients with different stages of
lung adenocarcinoma to identify key
microRNAs and their targets associated with patient outcomes. CIBERSORT was used for estimating the proportions of immune cells in various lung tissues. Significantly different adaptive and innate immune cell types, including memory B cells, CD8+ T cells, resting dendritic cells, and resting mast cells, were selected. Comparative studies and survival analyses were carried out. We found that potential genes and
microRNAs involved in immune responses were associated with patient outcomes. Specifically, miR-582/CD1B, which are involved in resting and activated dendritic cells, may be potential novel
biomarkers for
immunotherapy. An independent dataset of
miRNA microarray profiles was used to validate the expression of mature miR-582-5p in patients with advanced
lung adenocarcinoma. Alternative treatments, including
immunotherapies and
chemotherapy, are urgently needed to improve outcomes in patients with
lung cancer. Thus, our findings could provide insights into the selection of novel
microRNAs targeting immune genes and could improve the efficacy of
immunotherapy by disrupting
tumor function and promoting immune infiltration in patients with advanced
lung adenocarcinoma.